Production (Stage)
Brainstorm Cell Therapeutics Inc.
BCLI
$1.24
$0.1412.73%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.86M | -2.97M | -2.71M | -2.54M | -3.40M |
| Total Depreciation and Amortization | 52.00K | 53.00K | 59.00K | 64.00K | 64.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 717.00K | 73.00K | -216.00K | 194.00K | 170.00K |
| Change in Net Operating Assets | 464.00K | 1.80M | -434.00K | 600.00K | 104.00K |
| Cash from Operations | -1.63M | -1.05M | -3.30M | -1.68M | -3.06M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | 12.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 12.00K | -- | -- | -- |
| Total Debt Issued | 900.00K | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 685.00K | 1.06M | -- | 4.37M | 2.54M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.50M | -- | -- | -- | -- |
| Cash from Financing | 3.09M | 1.06M | -- | 4.37M | 2.54M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.46M | 22.00K | -3.30M | 2.69M | -524.00K |